In this study, we first defined that GALNT2 expression was high in GBM, GSCs, and IDH1 wildtype gliomas, and elevated GALNT2 expression was also associated with unfavorable GBM patients’ clinical outcomes. This evidence concerns the gene IDH1 and glioblastoma.